These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8944417)

  • 1. The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis.
    Aguejouf O; Oualane FA; Inamo J; Imbault P; Doutremepuich F; Millet J; Theveniaux J; Doutremepuich C
    Semin Thromb Hemost; 1996; 22(4):327-33. PubMed ID: 8944417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic and biochemical profiles of new venous antithrombotic beta-D-xyloside derivatives: potential antiathero/thrombotic drugs.
    Martin NB; Masson P; Sepulchre C; Theveniaux J; Millet J; Bellamy F
    Semin Thromb Hemost; 1996; 22(3):247-54. PubMed ID: 8836009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of external electrical stimulation on laser-beam-induced experimental thrombosis.
    Aguejouf O; Doutremepuich F; Doutremepuich C
    Pathophysiol Haemost Thromb; 2006; 35(5):364-9. PubMed ID: 17230037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The venous antithrombotic effect of LF 1351 in the rat following oral administration.
    Millet J; Theveniaux J; Brown NL
    Thromb Haemost; 1992 Jan; 67(1):176-9. PubMed ID: 1615473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
    Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
    Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The venous antithrombotic profile of naroparcil in the rabbit.
    Millet J; Theveniaux J; Brown NL
    Thromb Haemost; 1994 Dec; 72(6):874-9. PubMed ID: 7740457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
    Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombotic properties of heparin independent of its anticoagulant activity].
    Krupiński K; Bielawiec M; Breddin HK
    Acta Haematol Pol; 1994; 25(3):243-51. PubMed ID: 7992597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
    Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
    Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
    Vogel GM; van Amsterdam RG; Zandberg P; van Houwelingen P; Kop WJ; van Mensvoort FW; Meuleman DG
    Thromb Haemost; 1997 Jan; 77(1):183-9. PubMed ID: 9031471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model].
    Krupiński K; Breddin H; Bielawiec M
    Kardiol Pol; 1993 Aug; 39(8):100-4. PubMed ID: 8231003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
    Hiebert LM; Wice SM; Ping T; Herr D; Laux V
    Thromb Haemost; 2001 Jan; 85(1):114-8. PubMed ID: 11204561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests.
    Krupiński K; Ferber H; Breddin HK; Bielawiec M
    Acta Haematol Pol; 1994; 25(3):235-42. PubMed ID: 7992596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.